Related Experiment Video
Updated: Oct 9, 2026

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
Towards broader-spectrum direct-acting antivirals against RNA viruses
Hendrik Jan Thibaut1, Dirk Jochmans1, Christophe Van Dijck2
1KU Leuven Department of Microbiology, Immunology and Transplantation, Antiviral Drug and Vaccine Research Group, Leuven, Belgium.
Abstract:
Small molecule antiviral drugs have transformed the management of infections such as those caused by HIV, hepatitis B virus, hepatitis C virus, herpesviruses and influenza viruses. Effective antiviral therapeutics remain unavailable for many other often life-threatening viral infections, many of which are caused by RNA viruses. The development of potent, safe and orally available antivirals is therefore essential both to address current unmet medical needs and to strengthen epidemic and pandemic preparedness. In this Review, we discuss the rationale for building a diversified portfolio of broader-spectrum antivirals against RNA viruses with activity spanning multiple genera, entire families or even crossing viral families. We provide a non-exhaustive overview of approved and investigational antiviral agents active against RNA viruses and discuss the biological determinants that underlie their antiviral spectrum. Finally, we outline the clinical development frameworks required to accelerate the evaluation of such drugs, in particular in the context of outbreaks.
More Related Videos
Related Concept Videos
Antiviral Nucleoside Inhibitors
Viruses with RNA Genomes
Inhibitors Of Virion Release
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Size and Structure of Viral Genomes

